Process for preparing an A2A-adenosine receptor agonist and...

Details Process for preparing an A2A-adenosine receptor agonist and... Process for preparing an A2A-adenosine receptor agonist and...

2011-06-07

2011-06-07

Crane, Lawrence E (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S027630, C536S027700

Reexamination Certificate

active

07956179

ABSTRACT:
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4089959 (1978-05-01), Diamond
patent: 4120947 (1978-10-01), Diamond
patent: 4325956 (1982-04-01), Kjellin et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4593095 (1986-06-01), Snyder et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4804664 (1989-02-01), Kjellin et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5032252 (1991-07-01), Owen et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5189027 (1993-02-01), Miyasita et al.
patent: 5270304 (1993-12-01), Kogi et al.
patent: 5459254 (1995-10-01), Yamaguchi et al.
patent: 5516894 (1996-05-01), Reppert
patent: 5593975 (1997-01-01), Cristalli
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5641784 (1997-06-01), Kufner-Muhl et al.
patent: 5646156 (1997-07-01), Jacobsen et al.
patent: 5670498 (1997-09-01), Suzuki et al.
patent: 5703085 (1997-12-01), Suzuki et al.
patent: 5704491 (1998-01-01), Graves
patent: 5705491 (1998-01-01), Yamada
patent: 5770716 (1998-06-01), Khan et al.
patent: 5776960 (1998-07-01), Oppong et al.
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5939543 (1999-08-01), Morozumi et al.
patent: 6026317 (2000-02-01), Verani
patent: 6117878 (2000-09-01), Linden
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6368573 (2002-04-01), Leung
patent: 6387913 (2002-05-01), Mustafa
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6599283 (2003-07-01), Marzilli et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6642210 (2003-11-01), Zablocki et al.
patent: 6670334 (2003-12-01), Linden et al.
patent: 6677336 (2004-01-01), Zablocki et al.
patent: 6770634 (2004-08-01), Zablocki et al.
patent: 6825349 (2004-11-01), Kalla et al.
patent: 6855818 (2005-02-01), Zablocki et al.
patent: 6916804 (2005-07-01), Castelhano et al.
patent: 6977300 (2005-12-01), Kalla et al.
patent: 6995148 (2006-02-01), Jones et al.
patent: 7109180 (2006-09-01), Zablocki et al.
patent: 7109203 (2006-09-01), Hart et al.
patent: 7125993 (2006-10-01), Elzein et al.
patent: 7144872 (2006-12-01), Zablocki et al.
patent: 7183264 (2007-02-01), Zablocki et al.
patent: 7553823 (2009-06-01), Zablocki et al.
patent: 7582617 (2009-09-01), Belardinelli et al.
patent: 7655636 (2010-02-01), Gordi et al.
patent: 7655637 (2010-02-01), Zablocki et al.
patent: 7671192 (2010-03-01), Zablocki et al.
patent: 7683037 (2010-03-01), Belardinelli
patent: 7732595 (2010-06-01), Zablocki et al.
patent: 2002/0012946 (2002-01-01), Belardinelli et al.
patent: 2003/0235555 (2003-12-01), Shealey et al.
patent: 2004/0137533 (2004-07-01), Belardinelli et al.
patent: 2005/0020915 (2005-01-01), Belardinelli et al.
patent: 2006/0159621 (2006-07-01), Barrett
patent: 2006/0159627 (2006-07-01), Zheng et al.
patent: 2007/0265445 (2007-11-01), Zablocki et al.
patent: 2007/0299089 (2007-12-01), Belardinelli et al.
patent: 2008/0170990 (2008-07-01), Lieu et al.
patent: 2008/0213165 (2008-09-01), Lieu et al.
patent: 2008/0267861 (2008-10-01), Lieu et al.
patent: 2009/0081120 (2009-03-01), Lieu et al.
patent: 2009/0317331 (2009-12-01), Belardinelli et al.
patent: 2010/0081810 (2010-04-01), Zablocki et al.
patent: 2010/0086483 (2010-04-01), Belardinelli et al.
patent: 965411 (1975-04-01), None
patent: 2064742 (1991-12-01), None
patent: 0 354 638 (1990-02-01), None
patent: 0 386 683 (1990-09-01), None
patent: SHO 48-26038 (1973-08-01), None
patent: HEI 5 1993 9197 (1993-01-01), None
patent: WO 92/00297 (1992-01-01), None
patent: WO 92/12260 (1992-07-01), None
patent: WO 93/23401 (1993-11-01), None
patent: WO 93/25677 (1993-12-01), None
patent: WO 95/11681 (1995-05-01), None
patent: WO 98/52611 (1998-11-01), None
patent: WO 98/57651 (1998-12-01), None
patent: WO 99/63938 (1999-12-01), None
patent: WO 00/78778 (2000-12-01), None
patent: WO 00/78779 (2000-12-01), None
patent: WO 01/16134 (2001-08-01), None
patent: WO 01/62979 (2001-08-01), None
patent: WO 03/088978 (2003-10-01), None
patent: WO 2004/011010 (2004-02-01), None
patent: WO 2005/082379 (2005-09-01), None
patent: WO 2006/076698 (2006-07-01), None
patent: WO 2007/092372 (2007-08-01), None
patent: WO 2008/028140 (2008-03-01), None
patent: WO 2008/042796 (2008-04-01), None
patent: WO 2008/063712 (2008-05-01), None
patent: WO 2008/086096 (2008-07-01), None
patent: WO 2008/143667 (2008-11-01), None
patent: WO 2006/044856 (2009-04-01), None
patent: WO 2009/076580 (2009-06-01), None
patent: WO 2010/037122 (2010-04-01), None
Bergmann et al., “Oxidation of Hypoxanthines, Bearing 8-Aryl or 8-Pyridyl Substituents, by Bovine Milk Xanthine Oxidase,”, Biochimica et Biophysica Acta, vol. 484, No. 2, pp. 275-289 (1977).
Birdsall et al., “Purine N-Oxides-XL The 3-Acyloxypurine 8-Substitution Reaction: Scope: Syntheses of 8-Substituted Xanthines and Guanines,” Tetrahedron, vol. 27, pp. 5969-5978 (1971).
Blackburn et al., “Adenosine Mediates IL-13-Induced Inflammation and Remodeling in the Lung and interacts in an IL13-Adenosine Amplification Pathway,” J. Clin. Invest. vol. 112, No. 3, pp. 332-344 (2003).
Bruns, “Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts,” Biochemical Pharmacology, vol. 30, No. 4, pp. 325-333 (1981).
Buckle et al., “Inhibition of Cyclic Nucleotide Phosphodiesterase by Derivatives of 1,3-Bis(cyclopropylmethyl)xanthine,” J. Med. Chem., vol. 37, pp. 476-485 (1994).
Cerqueira, “The Future of Pharmacologic Stress: Selective A2A Adenosine Receptor Agonists,” Am. J. Cardiol., vol. 94 (2A), pp. 33D-42D (2004).
Cline et al., “Coronary Artery Angiography Using Multislice Computed Tomography Images,” Circulation, vol. 102, pp. 1589-1590, XP002564059 (2000).
Crimi et al., “Purine Derivatives in the Study of Allergic Inflammation in Respiratory Diseases,” Allergy, vol. 52, No. 34, pp. 48-54 (1997).
Cristalli et al., “2-Alkynyl Derivatives of Adenosine 5′-N′ethyluronamide: Selective A2 Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggretation,” J. Med. Chem., vol. 37, pp. 1720-1726 (1994).
Cushley et al., “Inhaled Adenosine and Guanosine on Airway Resistance in Normal and Asthmatic Subjects,” Br. J. Clin. Pharmacol, vol. 15, No. 2, pp. 161-165 (1983).
Dalpiaz et al., “De Novo Analysis of Receptor Binding Affinity Data of Xanthine Adenosine Receptor Antagonists,” Arzneim-Forsch/Drug Res., vol. 45, No. 3, pp. 230-233 (1995).
Dhalla et al., “Tachycardia Caused by A2A Adenosine Receptor Agonists is Mediated by Direct Sympathoexcitation in Awake Rates,” Journal of Pharmacology and Experimental Therapeutics, USA, vol. 316, No. 2, pp. 695-702, XP009073100 (2006).
Driver et al., “Adenosine in Bronchoalveolar Lavage Fluid in Asthma,” Am. Rev. Respir. Dis., vol. 148, No. 1, pp. 91-97 (1993).
Elias et al., “Airway Remodeling in Asthma,” The Journal of Clinical Investigation, vol. 104, No. 8, pp. 1001-1006 (1999).
Erickson et al., “1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A1/A2Affinity”, J. Med. Chem., vol. 34, pp. 1431-1435 (1991).
Feoktistov et al., “Adenosine A2BReceptors: A Novel Therapeutic Target in Asthma,” Trends Pharmacol. Sci., vol. 19, pp. 148-153 (1998).
Feoktistov et al., “Hypoxia Modulates Adenos

Affiliated with

Also associated with

Rating

Process for preparing an A2A-adenosine receptor agonist and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for preparing an A2A-adenosine receptor agonist and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing an A2A-adenosine receptor agonist and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2625227